PL2698372T3 - Nowy związek imidazooksazynowy lub jego sól - Google Patents

Nowy związek imidazooksazynowy lub jego sól

Info

Publication number
PL2698372T3
PL2698372T3 PL12768337T PL12768337T PL2698372T3 PL 2698372 T3 PL2698372 T3 PL 2698372T3 PL 12768337 T PL12768337 T PL 12768337T PL 12768337 T PL12768337 T PL 12768337T PL 2698372 T3 PL2698372 T3 PL 2698372T3
Authority
PL
Poland
Prior art keywords
salt
oxazine compound
novel imidazo
imidazo
novel
Prior art date
Application number
PL12768337T
Other languages
English (en)
Inventor
Masayuki Nakamura
Kenji Niiyama
Kaori Kamijo
Mitsuru Ohkubo
Toshiyasu Shimomura
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of PL2698372T3 publication Critical patent/PL2698372T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL12768337T 2011-04-06 2012-04-05 Nowy związek imidazooksazynowy lub jego sól PL2698372T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011084880 2011-04-06
PCT/JP2012/059376 WO2012137870A1 (ja) 2011-04-06 2012-04-05 新規イミダゾオキサジン化合物又はその塩
EP12768337.3A EP2698372B1 (en) 2011-04-06 2012-04-05 Novel imidazo-oxazine compound or salt thereof

Publications (1)

Publication Number Publication Date
PL2698372T3 true PL2698372T3 (pl) 2016-07-29

Family

ID=46969260

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12768337T PL2698372T3 (pl) 2011-04-06 2012-04-05 Nowy związek imidazooksazynowy lub jego sól

Country Status (19)

Country Link
US (1) US8772283B2 (pl)
EP (1) EP2698372B1 (pl)
JP (1) JP5599941B2 (pl)
KR (1) KR101658274B1 (pl)
CN (1) CN103459400B (pl)
AU (1) AU2012239157B2 (pl)
BR (1) BR112013025732B1 (pl)
CA (1) CA2830367C (pl)
DK (1) DK2698372T3 (pl)
ES (1) ES2567605T3 (pl)
HU (1) HUE027509T2 (pl)
MX (1) MX342064B (pl)
MY (1) MY163187A (pl)
PH (1) PH12013501873A1 (pl)
PL (1) PL2698372T3 (pl)
RU (1) RU2578608C2 (pl)
SG (1) SG193327A1 (pl)
TW (1) TWI525097B (pl)
WO (1) WO2012137870A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2868660B1 (en) 2012-07-02 2017-12-27 Taiho Pharmaceutical Co., Ltd. Antitumor effect potentiator comprising an imidazooxazine compound
US20140275504A1 (en) * 2013-03-13 2014-09-18 Dow Agrosciences Llc Process for the preparation of certain triaryl rhamnose carbamates
DK3543355T3 (da) * 2013-06-20 2021-03-01 Taiho Pharmaceutical Co Ltd Fremgangsmåde til forudsigelse af terapeutisk effektivitet for pi3k/akt/mtor-hæmmer på basis af phlda1- eller pik3c2b-ekspression
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
PT3023100T (pt) 2013-07-18 2019-05-29 Taiho Pharmaceutical Co Ltd Fármaco antitumoral para administração intermitente de inibidor de fgfr
JPWO2016136928A1 (ja) * 2015-02-27 2017-08-31 大鵬薬品工業株式会社 イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法
DK3279202T3 (da) 2015-03-31 2020-08-17 Taiho Pharmaceutical Co Ltd Krystal af 3,5-disubstitueret benzenalkynylforbindelse
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20220110859A (ko) * 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
MX2020009762A (es) 2018-03-19 2021-01-08 Taiho Pharmaceutical Co Ltd Composicion farmaceutica que incluye alquil sulfato de sodio.
CN112888440A (zh) 2018-10-16 2021-06-01 豪夫迈·罗氏有限公司 Akt抑制剂在眼科中的用途
MA56549A (fr) 2019-06-21 2022-04-27 Taiho Pharmaceutical Co Ltd Méthode de traitement d'une tumeur maligne
WO2021055728A1 (en) 2019-09-18 2021-03-25 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
CR20220230A (es) 2019-10-28 2022-06-15 Merck Sharp & Dohme Inhibidores de pequeñas moléculas de mutante g12c de kras
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
US20230174518A1 (en) 2020-04-24 2023-06-08 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
EP4183395A4 (en) 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
US20240122937A1 (en) * 2021-02-01 2024-04-18 Taiho Pharmaceutical Co., Ltd. Treating cancer in patient with pten inactivating mutation
CN117769554A (zh) 2021-05-28 2024-03-26 大鹏药品工业株式会社 Kras突变蛋白的小分子抑制剂
TW202515582A (zh) 2023-08-24 2025-04-16 日商大塚製藥股份有限公司 西區嘧啶(cedazuridine)之固定劑量組合
US11970475B1 (en) 2023-09-05 2024-04-30 King Faisal University 4-(1-(2-Hydroxypropyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-3-ol as an antimicrobial compound
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Kras蛋白之小分子抑制劑
WO2025128834A1 (en) * 2023-12-15 2025-06-19 Alterome Therapeutics, Inc. Akt1 modulators
CN119912475B (zh) * 2025-03-06 2026-01-06 复旦大学 用作tlr2拮抗剂的化合物或其衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57212188A (en) 1981-06-25 1982-12-27 Sankyo Co Ltd Imidazobenzoxazine derivative and its preparation
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
DE602005026509D1 (de) * 2004-04-09 2011-04-07 Merck Sharp & Dohme Hemmer der akt aktivität
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
MX2010001745A (es) * 2007-08-14 2010-03-10 Bayer Schering Pharma Ag Imidazoles fusionados para el tratamiento del cancer.
US9451809B2 (en) 2008-05-29 2016-09-27 Nike, Inc. Article of footwear with a marking system
CA2726317A1 (en) * 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010088177A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8614221B2 (en) 2009-03-11 2013-12-24 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8975265B2 (en) * 2010-07-12 2015-03-10 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrimidines and —pyridines

Also Published As

Publication number Publication date
HK1188451A1 (zh) 2014-05-02
ES2567605T3 (es) 2016-04-25
MX342064B (es) 2016-09-12
KR101658274B1 (ko) 2016-09-22
DK2698372T3 (en) 2016-03-21
MX2013011429A (es) 2013-12-09
AU2012239157B2 (en) 2015-11-05
WO2012137870A1 (ja) 2012-10-11
KR20140039186A (ko) 2014-04-01
MY163187A (en) 2017-08-15
EP2698372B1 (en) 2016-02-03
EP2698372A4 (en) 2014-09-10
JP5599941B2 (ja) 2014-10-01
HUE027509T2 (en) 2016-10-28
AU2012239157A1 (en) 2013-09-26
CA2830367C (en) 2016-08-30
EP2698372A1 (en) 2014-02-19
US20140005185A1 (en) 2014-01-02
US8772283B2 (en) 2014-07-08
BR112013025732B1 (pt) 2022-02-22
CA2830367A1 (en) 2012-10-11
BR112013025732A2 (pt) 2016-12-13
SG193327A1 (en) 2013-10-30
CN103459400A (zh) 2013-12-18
TWI525097B (zh) 2016-03-11
PH12013501873A1 (en) 2013-10-14
TW201247679A (en) 2012-12-01
RU2578608C2 (ru) 2016-03-27
JPWO2012137870A1 (ja) 2014-07-28
RU2013149174A (ru) 2015-05-20
CN103459400B (zh) 2016-05-18

Similar Documents

Publication Publication Date Title
IL286152A (en) Modified imidazopyridinyl-aminopyridine compounds
PL2698372T3 (pl) Nowy związek imidazooksazynowy lub jego sól
ZA201401268B (en) Noribogaine salt ansolvates
ZA201401553B (en) Cyclopropaneamine compound
GB201114103D0 (en) Novel compounds
GB201106799D0 (en) Novel compounds
GB201107325D0 (en) Novel compounds
GB201112607D0 (en) Novel compounds
SG11201405318PA (en) Novel piperidine compound or salt thereof
SG11201402876UA (en) Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof
EP2717694A4 (en) NEW COMPOUNDS
GB201111704D0 (en) Novel compounds
PL2609093T3 (pl) Związek soli
EP2708540A4 (en) PYRIMIDO-DIAZEPINONE COMPOUND
GB201122305D0 (en) Novel compound
GB201112987D0 (en) Novel compound
GB201104669D0 (en) Compound
GB201121538D0 (en) Compound
GB201118102D0 (en) Compound
GB201113766D0 (en) Novel compounds
GB201111476D0 (en) Novel compounds
GB201101085D0 (en) Novel compounds
GB201118658D0 (en) Novel compounds
GB201121357D0 (en) Novel compounds
GB201103073D0 (en) Novel compounds